Targeting JNK-interacting-protein-1 (JIP1) sensitises osteosarcoma to doxorubicin.

Oncotarget · 2012 · PMC3717953 · PMID 23045411

Europe PMC DOI

hedged sentences

0.0001

closest p · 0.0× alpha

0.0800

boldest claim

The sentences

highly significantp = 1.0*E-04actually significant

siRNA against JIP1 appeared to elicit the most potent and highly significant enhancement of doxorubicin-induced cell kill (relative cytotoxicity = 8.6; p = 1.0*E-04; FDR = 2%).

also in 132,142 other papers

borderline significantp = 0.056so close (0.05 < p ≤ 0.1)

Patients with JIP1 negative tumours showed a better survival outcome (mean 12.0 years) compared to patients with JIP1 positive tumours (mean 9.1 years); this difference in overall survival is borderline significant (LogRank, p = 0.056).

also in 11,409 other papers

approached significancep = 0.08so close (0.05 < p ≤ 0.1)

This was significant in LM7 (p < 0.01) and MG-63 (p = 0.01) cells and approached significance in SaOS2 cells (p = 0.08).

also in 8,237 other papers

showed a trendno p-value reported

Patients with JIP1 positive tumours showed a trend to inferior overall survival.

also in 53,322 other papers

a strong trendno p-value reported

Thus, while JIP1 staining did not directly correlate to the response to chemotherapy, JIP1 positivity did show a strong trend towards inferior overall survival outcome, suggesting a possible role for outcome prediction in patients with OS.

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.